Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 7/20 | 0.52 |
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | CCR2 | P41597 | 9/20 | 0.40 |
| ▸ | PLD2 | O14939 | 2/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630682 | 1.00 | TACR3 (0.52) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL631968 | 0.96 | TACR3 (0.48) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL631969 | 0.96 | TACR3 (0.48) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL631161 | 0.95 | TACR3 (0.46) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL631160 | 0.95 | TACR3 (0.46) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL8185526 | 0.93 | TACR3 (0.51) | TACR3TACR1CCR2 | |
| SCHEMBL631567 | 0.91 | TACR3 (0.57) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL632085 | 0.90 | TACR3 (0.53) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL632423 | 0.88 | TACR1 (0.54) | TACR3TACR1CCR2PLD2PLD1 | |
| SCHEMBL631093 | 0.87 | TACR3 (0.52) | TACR3TACR1CCR2PLD2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | claimed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | claimed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | ADRB3, KCNK3, KCND3 | TACR3 28/4885TACR1 6/4885CCR2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.